Association of atherosclerosis with expression of the LILRB1 receptor by human NK and T-cells supports the infectious burden hypothesis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 10, 2011, Pages 2314-2321

  Romo, Neus ^a   Fitó, Montserrat ^b,f   Gumá, Mónica ^a   Sala, Joan ^c   García, Cosme ^b   Ramos, Rafel ^g   Muntasell, Aura ^b   Masiá, Rafel ^c   Bruguera, Jordi ^b   Subirana, Isaac ^b,e   Vila, Joan ^b,e   De Groot, Eric ^d   Elosua, Roberto ^b,e   Marrugat, Jaume ^b   López Botet, Miguel ^a,b  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c HOSPITAL JOSEP TRUETA   (Spain)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^f Instituto de Salud Carlos III   (Spain)

^g GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

Author keywords

atherosclerosis; leukocytes; risk factors; viruses

Indexed keywords

C REACTIVE PROTEIN; CD3 ANTIGEN; CD56 ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LILRB1 RECEPTOR; MEMBRANE RECEPTOR; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2A; NATURAL KILLER CELL RECEPTOR NKG2C; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERODIAGNOSIS; T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; ANTIGENS, CD; ANTIGENS, CD56; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; KILLER CELLS, NATURAL; LINEAR MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY C; RECEPTORS, IMMUNOLOGIC; RISK ASSESSMENT; RISK FACTORS; SPAIN; T-LYMPHOCYTES; TUNICA INTIMA; TUNICA MEDIA;

EID: 80052968582     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.233288     Document Type: Article

References (52)

1. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol. 2009;27:165-197.
2. Stoll G, Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke. 2006;37:1923-1932. (Pubitemid 44297753)
3. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6:508-519. (Pubitemid 43980523)
4. de Boer OJ, van der Wal AC, Becker AE. Atherosclerosis, inflammation, and infection. J Pathol. 2000;190:237-243. (Pubitemid 30141370)
5. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet. 1997;350:430-436. (Pubitemid 27331246)
6. Epstein SE, Zhu J, Burnett MS, Zhou YF, Vercellotti G, Hajjar D. Infection and atherosclerosis: potential roles of pathogen burden and molecular mimicry. Arterioscler Thromb Vasc Biol. 2000;20:1417-1420. (Pubitemid 30353867)
7. Rahel BM, Visseren FL, Suttorp MJ, Plokker TH, Kelder JC, de Jongh BM, Diepersloot RJ, Verkooyen RP, Bouter KP. Cytomegalovirus and chlamydia pneumoniae as predictors for adverse events and angina pectoris after percutaneous coronary intervention. Am Heart J. 2004;148: 670-675. (Pubitemid 39349388)
8. Johnston SC, Zhang H, Messina LM, Lawton MT, Dean D. Chlamydia pneumoniae burden in carotid arteries is associated with upregulation of plaque interleukin-6 and elevated C-reactive protein in serum. Arterioscler Thromb Vasc Biol. 2005;25:2648-2653. (Pubitemid 43732292)
9. Melnick JL, Hu C, Burek J, Adam E, DeBakey ME. Cytomegalovirus DNA in arterial walls of patients with atherosclerosis. J Med Virol. 1994;42:170-174. (Pubitemid 24077560)
10. Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, Rogers WJ, Crouse JR, Borrowdale SL, Schron E, Knirsch C. Azi-thromycin for the secondary prevention of coronary events. N Engl J Med. 2005;352:1637-1645. (Pubitemid 40530230)
11. Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, Cairns R, Skene AM. Antibiotic treatment of chlamydia pneumoniae after acute coronary syndrome. N Engl J Med. 2005;352: 1646-1654. (Pubitemid 40530231)
12. Elkind MS, Luna JM, Moon YP, Boden-Albala B, Liu KM, Spitalnik S, Rundek T, Sacco RL, Paik MC. Infectious burden and carotid plaque thickness: the northern Manhattan study. Stroke. 2010;41:e117-e122.
13. Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Victor A, Hafner G, Prellwitz W, Schlumberger W, Meyer J. Impact of infectious burden on progression of carotid atherosclerosis. Stroke. 2002; 33:2581-2586. (Pubitemid 35266427)
14. Smieja M, Gnarpe J, Lonn E, Gnarpe H, Olsson G, Yi Q, Dzavik V, McQueen M, Yusuf S. Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 2003;107:251-257. (Pubitemid 36135220)
15. Blum A, Peleg A, Weinberg M. Anti-cytomegalovirus (CMV) IgG antibody titer in patients with risk factors to atherosclerosis. Clin Exp Med. 2003;3:157-160. (Pubitemid 37491545)
16. Mueller C, Hodgson JM, Bestehorn HP, Brutsche M, Perruchoud AP, Marsch S, Roskamm H, Buettner HJ. Previous cytomegalovirus infection and restenosis after aggressive angioplasty with provisional stenting. J Interv Cardiol. 2003;16:307-313. (Pubitemid 37047126)
17. Fateh-Moghadam S, Bocksch W, Wessely R, Jager G, Hetzer R, Gawaz M. Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy. Transplantation. 2003;76:1470-1474. (Pubitemid 37467696)
18. Hsich E, Zhou YF, Paigen B, Johnson TM, Burnett MS, Epstein SE. Cytomegalovirus infection increases development of atherosclerosis in Apolipoprotein-E knockout mice. Atherosclerosis. 2001;156:23-28. (Pubitemid 32429591)
19. Vliegen I, Herngreen SB, Grauls GE, Bruggeman CA, Stassen FR. Mouse cytomegalovirus antigenic immune stimulation is sufficient to aggravate atherosclerosis in hypercholesterolemic mice. Atherosclerosis. 2005;181: 39-44. (Pubitemid 40804691)
20. Pass RF. Cytomegalovirus. In: Fields Virology. Knipe DM HPGDLR, ed. 2001. Lippincott, Williams & Wilkins, Philadelphia.
21. Koch S, Larbi A, Ozcelik D, Solana R, Gouttefangeas C, Attig S, Wikby A, Strindhall J, Franceschi C, Pawelec G. Cytomegalovirus infection: a driving force in human T cell immunosenescence. Ann NY Acad Sci. 2007;1114:23-35. (Pubitemid 350070409)
22. Moss P. The emerging role of cytomegalovirus in driving immune senescence: a novel therapeutic opportunity for improving health in the elderly. Curr Opin Immunol. 2010;22:529-534.
23. López-Botet M, Angulo A, Gumá M. Natural killer cell receptors for major histocompatibility complex class I and related molecules in cytomegalovirus infection. Tissue Antigens. 2004;63:195-203. (Pubitemid 38297253)
24. Stassen FR, Vega-Cordova X, Vliegen I, Bruggeman CA. Immune activation following cytomegalovirus infection: more important than direct viral effects in cardiovascular disease? J Clin Virol. 2006;35:349-353. (Pubitemid 43188987)
25. Zhu J, Shearer GM, Norman JE, Pinto LA, Marincola FM, Prasad A, Waclawiw MA, Csako G, Quyyumi AA, Epstein SE. Host response to cytomegalovirus infection as a determinant of susceptibility to coronary artery disease: sex-based differences in inflammation and type of immune response. Circulation. 2000;102:2491-2496.
26. Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH, Lanier LL, McMichael AJ. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391:795-799. (Pubitemid 28099678)
27. Lee N, Llano M, Carretero M, Ishitani A, Navarro F, López-Botet M, Geraghty DE. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci USA. 1998;95:5199-5204. (Pubitemid 28208575)
28. Gumá M, Angulo A, Vilches C, Gómez-Lozano N, Malats N, López-Botet M. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood. 2004;104:3664-3671. (Pubitemid 39564443)
29. Gumá M, Cabrera C, Erkizia I, Bofill M, Clotet B, Ruiz L, López-Botet M. Human cytomegalovirus infection is associated with increased proportions of NK cells that express the CD94/NKG2C receptor in aviremic HIV-1-positive patients. J Infect Dis. 2006;194:38-41.
30. Mela CM, Goodier MR. The contribution of cytomegalovirus to changes in NK cell receptor expression in HIV-1-infected individuals. J Infect Dis. 2007;195:158-159. (Pubitemid 44958238)
31. Monsivais-Urenda A, Noyola-Cherpitel D, Hernandez-Salinas A, García-Sepulveda C, Romo N, Baranda L, López-Botet M, González-Amaro R. Influence of human cytomegalovirus infection on the NK cell receptor repertoire in children. Eur J Immunol. 2010;40:1418-1427.
32. Gumá M, Budt M, Sáez A, Brckalo T, Hengel H, Angulo A, López-Botet M. Expansion of CD94/NKG2C + NK cells in response to human cytomegalovirus-infected fibroblasts. Blood. 2006;107:3624-3631.
33. Colonna M, Navarro F, Bellón T, Llano M, Garcia P, Samaridis J, Angman L, Cella M, López-Botet M. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med. 1997;186:1809-1818. (Pubitemid 27524591)
34. Cosman D, Fanger N, Borges L, Kubin M, Chin W, Peterson L, Hsu ML. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity. 1997;7:273-282. (Pubitemid 27392018)
35. Young NT, Uhrberg M, Phillips JH, Lanier LL, Parham P. Differential expression of leukocyte receptor complex-encoded Ig-like receptors correlates with the transition from effector to memory CTL. J Immunol. 2001;166:3933-3941. (Pubitemid 32224920)
36. Antrobus RD, Khan N, Hislop AD, Montamat-Sicotte D, Garner LI, Rickinson AB, Moss PA, Willcox BE. Virus-specific cytotoxic T lymphocytes differentially express cell-surface leukocyte immunoglobulin-like receptor-1, an inhibitory receptor for class I major histocompatibility complex molecules. J Infect Dis. 2005;191: 1842-1853. (Pubitemid 40705391)
37. Poon K, Montamat-Sicotte D, Cumberbatch N, McMichael AJ, Callan MF. Expression of leukocyte immunoglobulin-like receptors and natural killer receptors on virus-specific CD8 + T cells during the evolution of Epstein-Barr virus-specific immune responses in vivo. Viral Immunol. 2005;18:513-522.
38. Grau M, Subirana I, Elosua R, Solanas P, Ramos R, Masia R, Cordon F, Sala J, Juvinya D, Cerezo C, Fito M, Vila J, Covas MI, Marrugat J. Trends in cardiovascular risk factor prevalence (1995-2000-2005) in northeastern Spain. Eur J Cardiovasc Prev Rehabil. 2007;14:653-659. (Pubitemid 47556402)
39. de Groot E, van Leuven SI, Duivenvoorden R, Meuwese MC, Akdim F, Bots ML, Kastelein JJ. Measurement of carotid intima-media thickness to assess progression and regression of atherosclerosis. Nat Clin Pract Cardiovasc Med. 2008;5:280-288. (Pubitemid 351593910)
40. Vossen MT, Matmati M, Hertoghs KM, Baars PA, Gent MR, Leclercq G, Hamann J, Kuijpers TW, van Lier RA. CD27 defines phenotypically and functionally different human NK cell subsets. J Immunol. 2008;180: 3739-3745.
41. Vivier E, Anfossi N. Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future. Nat Rev Immunol. 2004;4:190-198. (Pubitemid 38339085)
42. Kuijpers TW, Baars PA, Dantin C, van den Burg M, van Lier RA, Roosnek E. Human NK cells can control CMV infection in the absence of T cells. Blood. 2008;112:914-915.
43. Bobryshev YV, Lord RS. Identification of natural killer cells in human atherosclerotic plaque. Atherosclerosis. 2005;180:423-427. (Pubitemid 41072916)
44. Nakajima T, Goek O, Zhang X, Kopecky SL, Frye RL, Goronzy JJ, Weyand CM. De novo expression of killer immunoglobulin-like receptors and signaling proteins regulates the cytotoxic function of CD4 T cells in acute coronary syndromes. Circ Res. 2003;93:106-113. (Pubitemid 36919697)
45. Lamar DL, Weyand CM, Goronzy JJ. Promoter choice and translational repression determine cell type-specific cell surface density of the inhibitory receptor CD85j expressed on different hematopoietic lineages. Blood. 2010;115:3278-3286.
46. Sáez-Borderias A, Gumá M, Angulo A, Bellosillo B, Pende D, López-Botet M. Expression and function of NKG2D in CD4+ T cells specific for human cytomegalovirus. Eur J Immunol. 2006;36: 3198-3206. (Pubitemid 44932721)
47. Spyridopoulos I, Hoffmann J, Aicher A, Brummendorf TH, Doerr HW, Zeiher AM, Dimmeler S. Accelerated telomere shortening in leukocyte subpopulations of patients with coronary heart disease: role of cytomegalovirus seropositivity. Circulation. 2009;120:1364-1372.
48. Bjorkström NK, Riese P, Heuts F, Andersson S, Fauriat C, Ivarsson MA, Bjorklund AT, Flodström-Tullberg M, Michaelsson J, Rottenberg ME, Guzman CA, Ljunggren HG, Malmberg KJ. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood. 2010;116: 3853-3864.
49. Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. Nature. 2009;457:557-561.
50. Romagnani C, Juelke K, Falco M, Morandi B, D'Agostino A, Costa R, Ratto G, Forte G, Carrega P, Lui G, Conte R, Strowig T, Moretta A, Munz C, Thiel A, Moretta L, Ferlazzo G. CD56bright CD16-killer Ig-like receptor-NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation. J Immunol. 2007;178:4947-4955. (Pubitemid 46595277)
51. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397. (Pubitemid 38419992)
52. Tuomilehto J, Kuulasmaa K. WHO MONICA Project: assessing CHD mortality and morbidity. Int J Epidemiol. 1989;18:S38-S45. (Pubitemid 19270190)